Definium Therapeutics, Inc. · NASDAQ:DFTX
Definium Therapeutics — Mind Medicine (MindMed) — Investor Presentation (July 2022)
37 slides from Definium Therapeutics's investor presentation, Jul 21, 2022
Slide 1: MindMed Corporate Overview July 2022
G0) MindMed Corporate July 2022
Slide 2: Disclaimer
Disclaimer Coutonary Note Regerding Forward-Looking Stotements CCoutionory Note Regerding Regulatory Matters Morte ond industry Dato Corporate Overview | July 2022 ©) MindMed
Slide 3: Corporate Overview
Corporate Overview | July 2022 3
Slide 4: Corporate Overview
Corporate Overview | July 2022 4
Slide 5: Scientific Advisory Board
Scientific Advisory Board Robert Malenka, MD, PhD Maria A Oquendo, MD, PhD Maurizio Fava, MD Or Foveiso wos He hos edited ight mechonitms, ond hot extensive experience of on advitorovoriout of tomoceucal ond botecwology componies chairs Tuts Academic Alors Committe, times nthe Reroture and with on h
Slide 6: Business Highlights
Business Highlights Our mission is to deliver on the therapeutic potential of psychedelics and other novel targets to treat brain health disorders Leader in developing psychedelic product candidates to treat brain health disorders Diversified pipeline of clinical programs targeting significant unmet
Slide 7: There is an Urgent Need for Better Treatments
There is an Urgent Need for Better Treatments Substantial opportunities exist to advance novel treatments for a wide range of brain health disorders > (S wo fe) 1-year prevalence of anxiety 5 21 Yo disorders in the US e@ @ee ®@ 7 = 5 (@) M US adults live with & chronic pain’ iS 6 8 6 3 O US deaths f
Slide 8: Advancing Multiple Generations of Drug Candidates
Advancing Multiple Generations of Drug Candidates Our strategy is to deliver on well-characterized psychedelic candidates and next generation candidates with enhanced drug profiles PIPELINE EXPAN CONCEPT + Clinical evidence of efficacy ew wets + Expanded clinical indications beret + Well-characteriz
Slide 9: Research & Development Pipeline
Research & Development Pipeline Our pipeline diversification offers potential opportunities across therapeutic areas and mechanisms of action psvcHlaTRy sro e402 .MOMA) Linn el SUBSTANCE USE DIsoRDERS Mesto eunicon HC pid Wace Mv4n20 150 Otte) Chonie Pain DISCOVERY & EARLY DEVELOPMENT WM-e28rocbogan
Slide 10: Advancing the Field with Strong IP & Strategic Competitive Moats
Advancing the Field with Strong IP & Strategic Competitive Moats MindMed protects innovation and market potential through intellectual property-oriented R&D strategies Strategic Life Cycle Management & Late-Stage IP Development Can Significantly Extend Market Protection FDA-granted NCE ‘exclusivity
Slide 11: Key Milestones
Key Milestones GAD First Patient Dosing Q2-Q3 2022 | Phase 2b MM-120 Chronic Pain Study Initiation LSD D-ta rtrate Q4 2022 | Phase 2 ESOE ESOE: cory sign of eicocy MindMed Corporate Overview | July 2022
Slide 12: MM-120 | Lead Candidate with Evidence Across Multiple Therapeutic Areas
MM-120 | Lead Candidate with Evidence Across Multiple Therapeutic Areas Extensive evidence of clinical benefit and mechanistic rationale in psychiatry, pain and substance use disorders * Rapid & sustained 3x Effect Size 19 Novel MOA that target: Pp affective disorder therapies’ 2nd Generation chroni
Slide 13: MM-120 | Emerging Treatment Paradigm for Brain Health Disorders
MM-120 | Emerging Treatment Paradigm for Brain Health Disorders MM-120 is a potent serotonin agonist with potential applications to a broad range of brain health disorders Global Brain Cs ctivity Placebo Entropic brain activity Increased singl excitability Layer V Psychedelic pyramidol drug delivere
Slide 14: MM-120 | Legacy of LSD Clinical Research in Psychiatric Disorders
MM-120 | Legacy of LSD Clinical Research in Psychiatric Disorders Building on decades of clinical research on LSD in anxiety and depression x FINDING: 21 STUDIES Anxiety, depression & PRIOR TO 1974? Anxiety, d 512 patients Up to 95% reduction in symptoms 2 Anxiety in terminal Effect size of 11 with
Slide 15: MM-120 | Evidence in Anxiety Disorders
MM-120 | Evidence in Anxiety Disorders Results from UHB's LSD-Assist study support MindMed's clinical development of MM-120 for GAD Rapid, durable and significant anxiolytic effects + Reduction in anxiety and depression symptoms; durable at 16 weeks post-treatment vs. placebo (p<0.007) + Clinical re
Slide 16: MM-120 | Phase 2b Generalized Anxiety Disorder (GAD)
MM-120 | Phase 2b Generalized Anxiety Disorder (GAD) Study design seeks to demonstrate dose-responsive effects and identify optimal dose for pivotal clinical trials reeaurnr | WMA204SDDLoteN) | neat: GAD 200 participants total (n=40/arm) ‘A Phase 2b Dose Optimization Study of a Single Dose of MM-120
Slide 17: MM-120 | Phase 2a Attention Deficit Disorder (ADHD)
MM-120 | Phase 2a Attention Deficit Disorder (ADHD) Proof of concept study design seeks to explore potential clinical response in ADHD PSYCHIATRY MM+120 (LSD D:tartiate)__—_Indicotion: ADHD EREEEAN 52 participants total (n=26/arm) Prep Dosing Secondary Endpoint MM-120 20 pg q3d AISRS. Placebo q3d Ra
Slide 18: MM-120 | Novel Applications in Chronic Pain
MM-120 | Novel Applications in Chronic Pain Preclinical and early clinical evidence provide support for unique mechanism of action and potential clinical activity KEY FINDINGS 100 ig reduced cumulative pain scores for KAST 1967" Terminal cancer pain 128 patients at least 12 hours post-treatment 1g (
Slide 19: Key Milestones
Key Milestones PK/PD Study Initiation | Q3 2022 | Phase 1 IIT MM-402 Phase 1 Study Initiation 2023 | Phase 1 R(-)-MDMA Corporate Overview | July 2022
Slide 20: No Approved Drugs for Core Symptoms of Autism Spectrum Disorder (ASD)
No Approved Drugs for Core Symptoms of Autism Spectrum Disorder (ASD) Growing prevalence and impact of ASD yields an urgent need for novel therapies that target core symptoms and align with patient preferences MM-402 Activity Aligns with Reported Needs and Desired Benefits for Individuals with ASD 5
Slide 21: MM-402 | Clinical Data Support Opportunity in ASD
MM-402 | Clinical Data Support Opportunity in ASD Pilot clinical trial results of MDMA demonstrate acute and durable positive effects on social functioning in ASD population’ S) DMA is siphermacelosically MDMA Reduces Social Anxiety in ASD optimized enantiomer of MD! + Potential first in class thera
Slide 22: MM-402 | Preclinical Data Indicate Potential Enhanced Benefit/Risk Profile
MM-402 | Preclinical Data Indicate Potential Enhanced Benefit/Risk Profile Preclinical data suggest the R-enantiomer of MDMA has enhanced prosocial effects with an improved safety profile gest that R(-}-MDMA Maintains Prosocial Effects with Translational preclinical data su R(-)-M| Reduced Stimulant
Slide 23: MM-110 Zolunicant HCl
MM-110 Zolunicant HCl Corporate Overview | July 2022 23
Slide 24: MM-110 | Novel Mechanism to Address a Critical Gap in OUD Treatment
MM-110 | Novel Mechanism to Address a Critical Gap in OUD Treatment Mechanism of action and target product profile complement standard-of-care and address a critical gap in available treatment landscape Opioid Initiation Opioid Use Disorder MM-110-facilitated Supervised Withdrawal & Medication Assis
Slide 25: MM-110 | Strong Preclinical Efficacy on Key Translational Outcomes
MM-110 | Strong Preclinical Efficacy on Key Translational Outcomes A single dose of MM-110 mitigates withdrawal symptoms and opioid self-administration in preclinical models” Reduction in Translational Markers of Opioid Withdrawal Reduction in Translational Markers of OUD Withdrawal Sym, (Teeth Ch P
Slide 26: MM-110 | Phase 1 Study Results - Key Takeaways
MM-110 | Phase 1 Study Results - Key Takeaways Phase 1 study results support progression of MM-110 (zolunicant) into planned upcoming Phase 2 clinical program + Well-tolerated up to 500 mg per day in Single Ascending Dose (SAD) and 60 mg per day in the Multiple Ascending Dose (MAD) + Linear PK maint
Slide 27: Collaborations & Early R&D
Collaborations & Early R&D ©} MindMed Corporate Overview | July 2022 2
Slide 28: External Collaborations Accelerate Discovery & Development
External Collaborations Accelerate Discovery & Development Leveraging key partnerships and collaborations to accelerate drug discovery and de-risk clinical development NEW CHEMICAL ENTITY DISCOVERY ENGINE ADVANCED DRUG DELIVERY EFFICIENT CLINICAL PROVING GROUND DISCOVERY & BRAIN TARGETED LIPOSOMES R
Slide 29: Exclusive Collaboration with Leading Researchers
Exclusive Collaboration with Leading Researchers MindMed's exclusive collaboration with the Liechti Lab at UHB enables efficient evidence generation to support RED strategy Strategic Value LSD for Anxiety y + Rapid transition to - LSD for MDD ra . i clinical evidence generation LSD for Cluster Heada
Slide 30: Digital Medicine
Digital Medicine Corporate Overview | July 2022 30
Slide 31: Digital Unlocks Potential Opportunities Throughout the Product Lifecycle
Digital Unlocks Potential Opportunities Throughout the Product Lifecycle Generating data, insights, models, and tools from early Preclinical Research IND & Phoses 1-3 Drug Lounch e ®@ © through market Enhoncement and Lifecycle Management m~ Companion Products Clinical Development Tools — + Deep Digi
Slide 32: Digital Platform Will Add Value Through the Patient Journey
Digital Platform Will Add Value Through the Patient Journey Developing a scalable delivery platform to enable adoption leveraging the existing treatment ecosystem + Patient education, engagement, preparation + In-session monit. + Real world monitoring of trends + Deep digital diagnosis + Clinician d
Slide 33: Digital Enables Alignment of Incentives for Broad Market Access
Digital Enables Alignment of Incentives for Broad Market Access Complementary digital medicine products and studies for improved brain health outcomes 1 Measure, diagnose & engage tT ome a Community Support 2 duality care & documentation 3 clinicol decision support { — | = A. Patient trend predictio
Slide 34: Digital Pipeline Progression Aligns with Drug Development
Digital Pipeline Progression Aligns with Drug Development Executing across product categories with strong technical development and clinical research ‘TECHNOLOGY CANDIDATE “Anxiety & Affective Disorders Transdiagnostic DISCOVERY & REAL-WORLD DATA : — — In Development In Development ‘Anxiety Disorder
Slide 35: Corporate Information
Corporate Information © MindMed
Slide 36: NEO: MMED
NASDAQ: MNMD // NEO: MMED First Publicly Listed Company Developing Psychedelic Product Candidates ‘OWNERSHIP AS OF MARCH 31, 2022 EXECUTIVE TEAM/DIRECTORS/INSIDERS. 4796490 NON-INSIDER SHARES 377308827 EQUITY INCENTIVE PLAN (ISSUED) 46,269,703 ‘OUTSTANDING WARRANTS 2539991 TOTAL (FULLY DILUTED) 4907
Slide 37: MindMed
&) MindMed <3 MindMed Corporate Overview | July 2022 7
Mind Medicine (MindMed) — Investor Presentation (July 2022) on 6ix